[1]

Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, et al. 2024. TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Research 52:D1465−D1477

doi: 10.1093/nar/gkad751
[2]

Manglik A, Kobilka B. 2014. The role of protein dynamics in GPCR function: insights from the β2AR and rhodopsin. Current Opinion in Cell Biology 27:136−143

doi: 10.1016/j.ceb.2014.01.008
[3]

Hauser AS, Attwood MM, Rask-Andersen M, Schiöth HB, Gloriam DE. 2017. Trends in GPCR drug discovery: new agents, targets and indications. Nature Reviews Drug Discovery 16:829−842

doi: 10.1038/nrd.2017.178
[4]

Wu B, Chien EYT, Mol CD, Fenalti G, Liu W, et al. 2010. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330:1066−1071

doi: 10.1126/science.1194396
[5]

Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SGF, Thian FS, et al. 2007. GPCR engineering yields high-resolution structural insights into β2-adrenergic receptor function. Science 318:1266−1273

doi: 10.1126/science.1150609
[6]

Cohen P. 2002. Protein kinases — the major drug targets of the twenty-first century? Nature Reviews Drug Discovery 1:309−315

doi: 10.1038/nrd773
[7]

Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, et al. 2008. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences 105:2070−2075

doi: 10.1073/pnas.0709662105
[8]

Noble MEM, Endicott JA, Johnson LN. 2004. Protein kinase inhibitors: insights into drug design from structure. Science 303:1800−1805

doi: 10.1126/science.1095920
[9]

Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, et al. 2017. The target landscape of clinical kinase drugs. Science 358:eaan4368

doi: 10.1126/science.aan4368
[10]

Attwood MM, Fabbro D, Sokolov AV, Knapp S, Schiöth HB. 2021. Trends in kinase drug discovery: targets, indications and inhibitor design. Nature Reviews Drug Discovery 20:839−861

doi: 10.1038/s41573-021-00252-y
[11]

Rawlings ND, Barrett AJ, Thomas PD, Huang X, Bateman A, et al. 2018. The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database. Nucleic Acids Research 46:D624−D632

doi: 10.1093/nar/gkx1134
[12]

Rawlings ND, Barrett AJ. 1993. Evolutionary families of peptidases. Biochemical Journal 290:205−218

doi: 10.1042/bj2900205
[13]

Raj VS, Mou H, Smits SL, Dekkers DHW, Müller MA, et al. 2013. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495:251−254

doi: 10.1038/nature12005
[14]

Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. 2017. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 136:849−870

doi: 10.1161/CIRCULATIONAHA.117.028136
[15]

Zhou CK, Liu ZZ, Peng ZR, Luo XY, Zhang XM, et al. 2025. M28 family peptidase derived from Peribacillus frigoritolerans initiates trained immunity to prevent MRSA via the complosome-phosphatidylcholine axis. Gut Microbes 17:2484386

doi: 10.1080/19490976.2025.2484386
[16]

Hörlein AJ, Näär AM, Heinzel T, Torchia J, Gloss B, et al. 1995. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377:397−404

doi: 10.1038/377397a0
[17]

Chen JD, Evans RM. 1995. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454−457

doi: 10.1038/377454a0
[18]

Zhang M, Xie X, Chen E, Guo Y, Wang H, et al. 2025. The ribonucleoprotein hnRNP K promotes hepatic steatosis by suppressing the nuclear hormone receptor PPARα. Journal of Biological Chemistry 301:110500

doi: 10.1016/j.jbc.2025.110500
[19]

Jefferson WN, Wang T, Padilla-Banks E, Williams CJ. 2024. Unexpected nuclear hormone receptor and chromatin dynamics regulate estrous cycle dependent gene expression. Nucleic Acids Research 52:10897−10917

doi: 10.1093/nar/gkae714
[20]

Vlamis-Gardikas A, Aslund F, Spyrou G, Bergman T, Holmgren A. 1997. Cloning, overexpression, and characterization of glutaredoxin 2, an atypical glutaredoxin from Escherichia coli. Journal of Biological Chemistry 272:11236−11243

doi: 10.1074/jbc.272.17.11236
[21]

Abdelwaly A, Helal MA, Fathy MM, Alaaeldeen H, Klein ML, et al. 2025. Design and synthesis of novel small molecules targeting the Kv1.3 voltage-gated potassium ion channel. Scientific Reports 15:32756

doi: 10.1038/s41598-025-18086-8
[22]

Kariev AM, Green ME. 2025. H+ and confined water in gating in many voltage-gated potassium channels: ion/water/counterion/protein networks and protons added to gate the channel. International Journal of Molecular Sciences 26:7325

doi: 10.3390/ijms26157325
[23]

Catterall WA, Cestèle S, Yarov-Yarovoy V, Yu FH, Konoki K, et al. 2007. Voltage-gated ion channels and gating modifier toxins. Toxicon 49:124−141

doi: 10.1016/j.toxicon.2006.09.022
[24]

Isom LL, De Jongh KS, Catterall WA. 1994. Auxiliary subunits of voltage-gated ion channels. Neuron 12:1183−1194

doi: 10.1016/0896-6273(94)90436-7
[25]

Lai HC, Jan LY. 2006. The distribution and targeting of neuronal voltage-gated ion channels. Nature Reviews Neuroscience 7:548−562

doi: 10.1038/nrn1938
[26]

Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, et al. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479−490

doi: 10.1016/j.immuni.2005.09.015
[27]

Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, et al. 2009. Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. The Journal of Immunology 183:787−791

doi: 10.4049/jimmunol.0901363
[28]

Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, et al. 2003. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nature Immunology 4:69−77

doi: 10.1038/ni875
[29]

Kunze R, Navratil F, Beichert J, Geyer F, Floss DM, et al. 2025. iBody-mediated tuning of synthetic cytokine receptor activation via rational nanobody interface engineering. mAbs 17:2563009

doi: 10.1080/19420862.2025.2563009
[30]

Naz F, Arish M, Singh S, Naqvi N, Alam A. 2025. Mycobacterium tuberculosis PE5 stimulates anti-inflammatory cytokine production via innate immune toll-like receptor 4 signaling. Microbial Pathogenesis 208:107966

doi: 10.1016/j.micpath.2025.107966
[31]

Ercan M, Fırat Oğuz E, Özcan M, Alp HH. 2026. Within- and Between-Subject biological variation estimates of serum free light immunoglobulin chains in healthy individuals in Turkey. Clinica Chimica Acta 578:120545

doi: 10.1016/j.cca.2025.120545
[32]

Wang Y, Liu N, Zou Y, Jie J, Liu Z, et al. 2026. A robust label-free workflow for the immunoglobulin G subclass site-specific N-glycopeptides and the glycosylation of IgG 2 correlated with colorectal cancer. Talanta 296:128326

doi: 10.1016/j.talanta.2025.128326
[33]

Ishida Y, Agata Y, Shibahara K, Honjo T. 1992. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. The EMBO Journal 11:3887−3895

doi: 10.1002/j.1460-2075.1992.tb05481.x
[34]

van Dongen JJM, Langerak AW, Brüggemann M, Evans PAS, Hummel M, et al. 2003. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 17:2257−2317

doi: 10.1038/sj.leu.2403202
[35]

Rief M, Gautel M, Oesterhelt F, Fernandez JM, Gaub HE. 1997. Reversible unfolding of individual titin immunoglobulin domains by AFM. Science 276:1109−1112

doi: 10.1126/science.276.5315.1109
[36]

Guo H, Ingolia NT, Weissman JS, Bartel DP. 2010. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466:835−40

doi: 10.1038/nature09267
[37]

Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, et al. 2020. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nature Nanotechnology 15:313−320

doi: 10.1038/s41565-020-0669-6
[38]

Llave C, Xie Z, Kasschau KD, Carrington JC. 2002. Cleavage of scarecrow-like mRNA targets directed by a class of Arabidopsis miRNA. Science 297:2053−2056

doi: 10.1126/science.1076311
[39]

Yoon JH, Abdelmohsen K, Srikantan S, Yang X, Martindale Jennifer L, et al. 2012. LincRNA-p21 suppresses target mRNA translation. Molecular Cell 47:648−655

doi: 10.1016/j.molcel.2012.06.027
[40]

Luo PK, Chang WA, Peng SY, Chu LA, Chuang YH, et al. 2026. Endogenous macrophages as "Trojan horses" for targeted oral delivery of mRNA-encoded cytokines in tumor microenvironment immunotherapy. Biomaterials 325:123620

doi: 10.1016/j.biomaterials.2025.123620
[41]

Xiong XC, Zhang NN, Wu M, Cao TS, Deng K, et al. 2025. Development and characterization of a bivalent mRNA vaccine targeting the Delta and Omicron variants of SARS-CoV-2. Human Vaccines & Immunotherapeutics 21:2562730

doi: 10.1080/21645515.2025.2562730
[42]

Hou X, Zaks T, Langer R, Dong Y. 2021. Lipid nanoparticles for mRNA delivery. Nature Reviews Materials 6:1078−1094

doi: 10.1038/s41578-021-00358-0
[43]

Tenchov R, Bird R, Curtze AE, Zhou Q. 2021. Lipid nanoparticles─from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano 15:16982−17015

doi: 10.1021/acsnano.1c04996
[44]

Ouranidis A, Vavilis T, Mandala E, Davidopoulou C, Stamoula E, et al. 2022. mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles. Biomedicines 10:50

doi: 10.3390/biomedicines10010050
[45]

Lu RM, Hsu HE, Perez SJLP, Kumari M, Chen GH, et al. 2024. Current landscape of mRNA technologies and delivery systems for new modality therapeutics. Journal of Biomedical Science 31:89

doi: 10.1186/s12929-024-01080-z
[46]

Zhang M, Hussain A, Yang H, Zhang J, Liang XJ, et al. 2023. mRNA-based modalities for infectious disease management. Nano Research 16:672−691

doi: 10.1007/s12274-022-4627-5
[47]

Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, et al. 2019. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 575:688−692

doi: 10.1038/s41586-019-1705-2
[48]

Mazel D, Pochet S, Marlière P. 1994. Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation. The EMBO Journal 13:914−923

doi: 10.1002/j.1460-2075.1994.tb06335.x
[49]

Jadhav R, Shekar A, Westenhaver Z, Skandhan A. 2025. Abstract 4370073: a delayed diagnosis of anti-HMG-CoA reductase immune-mediated necrotizing myopathy. Circulation 152:A4370073

doi: 10.1161/circ.152.suppl_3.4370073
[50]

Leitans J, Kazaks A, Balode A, Ivanova J, Zalubovskis R, et al. 2015. Efficient Expression and Crystallization System of Cancer-Associated Carbonic Anhydrase Isoform IX. Journal of Medicinal Chemistry 58:9004−09

doi: 10.1021/acs.jmedchem.5b01343
[51]

Ruusuvuori E, Hong L, Huttu K, Palva JM, Smirnov S, et al. 2004. Carbonic anhydrase isoform VII acts as a molecular switch in the development of synchronous gamma-frequency firing of hippocampal CA1 pyramidal cells. The Journal of Neuroscience 24:2699−2707

doi: 10.1523/JNEUROSCI.5176-03.2004
[52]

Temperini C, Scozzafava A, Vullo D, Supuran CT. 2006. Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII, and XIV with l- and d-histidine and crystallographic analysis of their adducts with isoform II: engineering proton-transfer processes within the active site of an enzyme. Chemistry 12:7057−66

doi: 10.1002/chem.200600159
[53]

Kamel EM, Ahmed NA, Maodaa S, Abuamarah BA, Othman SI, et al. 2025. Entrance-channel plugging by natural sulfonamide antibiotics yields isoform-selective carbonic anhydrase IX inhibitors: an integrated in silico/ in vitro discovery of the lead SB-203207. BMC Chemistry 19:263

doi: 10.1186/s13065-025-01634-8
[54]

Torres SW, Lan C, Harthorn A, Schmitz Z, Blanchard PL, et al. 2025. Molecular determinants of affinity and isoform selectivity in protein─small molecule hybrid inhibitors of carbonic anhydrase. Bioconjugate Chemistry 36:549−562

doi: 10.1021/acs.bioconjchem.5c00006
[55]

Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, et al. 2004. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 329:593

doi: 10.1136/bmj.38184.606169.ae
[56]

Scozzafava A, Supuran CT. 2000. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. Journal of Medicinal Chemistry 43:3677−3687

doi: 10.1021/jm000027t
[57]

Mori M, Li G, Abe I, Nakayama J, Guo Z, et al. 2006. Lanosterol synthase mutations cause cholesterol deficiency–associated cataracts in the Shumiya cataract rat. The Journal of Clinical Investigation 116:395−404

doi: 10.1172/jci20797
[58]

Mullins EA, Francois JA, Kappock TJ. 2008. A specialized citric acid cycle requiring succinyl-coenzyme A (CoA): acetate CoA-transferase (AarC) confers acetic acid resistance on the acidophile Acetobacter aceti. Journal of Bacteriology 190:4933−4940

doi: 10.1128/JB.00405-08
[59]

Kusano H, Li H, Minami H, Kato Y, Tabata H, et al. 2019. Evolutionary developments in plant specialized metabolism, exemplified by two transferase families. Frontiers in Plant Science 10:794

doi: 10.3389/fpls.2019.00794
[60]

Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, et al. 2004. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Pflügers Archiv 447:465−468

doi: 10.1007/s00424-003-1192-y
[61]

César-Razquin A, Snijder B, Frappier-Brinton T, Isserlin R, Gyimesi G, et al. 2015. A call for systematic research on solute carriers. Cell 162:478−487

doi: 10.1016/j.cell.2015.07.022
[62]

Palmiter RD, Huang L. 2004. Efflux and compartmentalization of zinc by members of the SLC30 family of solute carriers. Pflügers Archiv 447:744−751

doi: 10.1007/s00424-003-1070-7
[63]

Kirii M, Yoshida Y, Takashima S, Uchio-Yamada K, Oh-hashi K. 2025. Transcriptional regulation of solute carrier family 6 member 9 gene. Molecular Biology Reports 52:540

doi: 10.1007/s11033-025-10591-3
[64]

Ren X, Li W. 2025. Iron-handling solute carrier SLC22A17 as a blood–brain barrier target after stroke. Neural Regeneration Research 20:3207−3208

doi: 10.4103/NRR.NRR-D-24-00811
[65]

Markadieu N, Delpire E. 2014. Physiology and pathophysiology of SLC12A1/2 transporters. Pflügers Archiv - European Journal of Physiology 466:91−105

doi: 10.1007/s00424-013-1370-5
[66]

Yokomori T, Tozaki T, Ohnuma A, Ishimaru M, Sato F, et al. 2024. Non-synonymous substitutions in Cadherin 13, solute carrier family 6 member 4, and monoamine oxidase A genes are associated with personality traits in thoroughbred horses. Behavior Genetics 54:333−341

doi: 10.1007/s10519-024-10186-x
[67]

Brown KK, Hann MM, Lakdawala AS, Santos R, Thomas PJ, et al. 2018. Approaches to target tractability assessment - a practical perspective. Medchemcomm 9:606−613

doi: 10.1039/C7MD00633K
[68]

Ou B, Hampsch-Woodill M, Prior RL. 2001. Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe. Journal of Agricultural and Food Chemistry 49:4619−4626

doi: 10.1021/jf010586o
[69]

Gulati P, Taneja S, Ramasamy SK. 2026. Recent progress and developments on phenothiazine-based fluorescence probe for hypochlorous acid sensing. Journal of Molecular Structure 1349:143837

doi: 10.1016/j.molstruc.2025.143837
[70]

Matuskey D, Gallezot JD, Nabulsi N, Henry S, Torres K, et al. 2023. Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: a phase 1 study in healthy male adults. Journal of Psychopharmacology 37:164−71

doi: 10.1177/02698811221140008
[71]

Simon A, Nghiem KS, Gampe N, Garádi Z, Boldizsár I, et al. 2022. Stability study of Alpinia galanga constituents and investigation of their membrane permeability by ChemGPS-NP and the parallel artificial membrane permeability assay. Pharmaceutics 14:1967

doi: 10.3390/pharmaceutics14091967
[72]

Madras BK, Xie Z, Lin Z, Jassen A, Panas H, et al. 2006. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. The Journal of Pharmacology and Experimental Therapeutics 319:561−569

doi: 10.1124/jpet.106.106583
[73]

Verrico CD, Miller GM, Madras BK. 2007. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology 189:489−503

doi: 10.1007/s00213-005-0174-5
[74]

Bottalico B, Larsson I, Brodszki J, Hernandez-Andrade E, Casslén B, et al. 2004. Norepinephrine Transporter (NET), Serotonin Transporter (SERT), Vesicular Monoamine Transporter (VMAT2) and Organic Cation Transporters (OCT1, 2 and EMT) in human placenta from pre-eclamptic and normotensive pregnancies. Placenta 25:518−529

doi: 10.1016/j.placenta.2003.10.017
[75]

Meltzer PC, Butler D, Deschamps JR, Madras BK. 2006. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. Journal of Medicinal Chemistry 49:1420−1432

doi: 10.1021/jm050797a
[76]

Green H, Persson M, Wikström M, Monti MC. 2025. In vitro monoamine reuptake inhibition and forensic case series in Sweden of the synthetic cathinones 2-, 3-, and 4-Me-alpha-PiHP. Forensic Science International 377:112657

doi: 10.1016/j.forsciint.2025.112657
[77]

Persson M, Vikingsson S, Kronstrand R, Green H. 2024. Characterization of neurotransmitter inhibition for seven cathinones by a proprietary fluorescent dye method. Drug Testing and Analysis 16:339−347

doi: 10.1002/dta.3547
[78]

Sora I, Hall FS, Andrews AM, Itokawa M, Li XF, et al. 2001. Molecular mechanisms of cocaine reward: Combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proceedings of the National Academy of Sciences of the United States of America 98:5300−05

doi: 10.1073/pnas.091039298
[79]

Shen HW, Hagino Y, Kobayashi H, Shinohara-Tanaka K, Ikeda K, et al. 2004. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology 29:1790−1799

doi: 10.1038/sj.npp.1300476
[80]

Capuron L, Miller AH. 2011. Immune system to brain signaling: Neuropsychopharmacological implications. Pharmacology & Therapeutics 130:226−238

doi: 10.1016/j.pharmthera.2011.01.014
[81]

Nakatsuka N, Yang KA, Abendroth JM, Cheung KM, Xu X, et al. 2018. Aptamer–field-effect transistors overcome Debye length limitations for small-molecule sensing. Science 362:319−324

doi: 10.1126/science.aao6750
[82]

Marder SR, Davis JM, Chouinard G. 1997. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. The Journal of Clinical Psychiatry 58:538−546

doi: 10.4088/jcp.v58n1205
[83]

Daw ND, Kakade S, Dayan P. 2002. Opponent interactions between serotonin and dopamine. Neural Networks 15:603−616

doi: 10.1016/S0893-6080(02)00052-7
[84]

Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, et al. 2003. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400−1411

doi: 10.1038/sj.npp.1300203
[85]

Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, et al. 2001. 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. Journal of Neurochemistry 76:1521−1531

doi: 10.1046/j.1471-4159.2001.00154.x
[86]

Brunello N, Masotto C, Steardo L, Markstein R, Racagni G. 1995. New Insights into the Biology of Schizophrenia through the Mechanism of Action of Clozapine. Neuropsychopharmacology 13:177−213

doi: 10.1016/0893-133X(95)00068-O
[87]

Łupina M, Wąsik A, Baranowska-Bosiacka I, Tarnowski M, Słowik T, et al. 2024. Acute and chronic exposure to linagliptin, a selective inhibitor of dipeptidyl peptidase-4 (DPP-4), has an effect on dopamine, serotonin and noradrenaline level in the striatum and hippocampus of rats. International Journal of Molecular Sciences 25:3008

doi: 10.3390/ijms25053008
[88]

Collin F, Karkare S, Maxwell A. 2011. Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Applied Microbiology and Biotechnology 92:479−497

doi: 10.1007/s00253-011-3557-z
[89]

Gradišar H, Pristovšek P, Plaper A, Jerala R. 2007. Green tea catechins inhibit bacterial DNA gyrase by interaction with its ATP binding site. Journal of Medicinal Chemistry 50:264−271

doi: 10.1021/jm060817o
[90]

Khalid M, Haider A, Shahzadi I, Ul-Hamid A, Imran M, et al. 2025. Dual functional samarium-chitosan doped CdTe nanoparticles: Dye degradation and bacterial inhibition targeting DHFR and DNA gyrase. Surfaces and Interfaces 72:107046

doi: 10.1146/annurev.pharmtox.38.1.97
[91]

Ferrero L, Cameron B, Manse B, Lagneaux D, Crouzet J, et al. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Molecular Microbiology 13:641−653

doi: 10.1111/j.1365-2958.1994.tb00458.x
[92]

Drlica K, Zhao X. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiology and Molecular Biology Reviews 61:377−392

doi: 10.1128/mmbr.61.3.377-392.1997
[93]

Aldred KJ, Kerns RJ, Osheroff N. 2014. Mechanism of Quinolone Action and Resistance. Biochemistry 53:1565−74

doi: 10.1021/bi5000564
[94]

Pham TDM, Ziora ZM, Blaskovich MAT. 2019. Quinolone antibiotics. Medchemcomm 10:1719−1739

doi: 10.1039/C9MD00120D
[95]

Patil GS, Gaikwad KN, Suryawanshi SS, Bhandurge P. 2025. A comprehensive review on discovery, development, the chemistry of quinolones, and their antimicrobial resistance. Current Topics in Medicinal Chemistry 00:1−16

doi: 10.2174/0115680266355989250730072511
[96]

Khanna A, Narang A, Thakur V, Singh K, Kumar N, et al. 2025. Design, synthesis, antibacterial evaluation, and molecular modelling studies of 1,2,3-triazole-linked coumarin-vanillin hybrids as potential DNA gyrase and topoisomerase IV inhibitors. Bioorganic Chemistry 164:108815

doi: 10.1016/j.bioorg.2025.108815
[97]

Zhu M, Tse MW, Weller J, Chen J, Blainey PC. 2021. The future of antibiotics begins with discovering new combinations. Annals of the New York Academy of Sciences 1496:82−96

doi: 10.1111/nyas.14649
[98]

Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, et al. 2000. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS Study: a randomized controlled trial. JAMA 284:1247−1255

doi: 10.1001/jama.284.10.1247
[99]

Vane JR, Bakhle YS, Botting RM. 1998. Cyclooxygenases 1 and 2. Annual Review of Pharmacology and Toxicology 38:97−120
[100]

Smith WL, DeWitt DL, Garavito RM. 2000. Cyclooxygenases: structural, cellular, and molecular biology. Annual Review of Biochemistry 69:145−182

doi: 10.1146/annurev.biochem.69.1.145
[101]

Abdul-Malik MA, El-Dean AMK, Hussein AHM, Abdelmonsef AH, Tolba MS. 2026. Synthesis, in silico and in vivo evaluation of new pyrazole-based thiosemicarbazones containing thiazole and thiazolone moieties as potential anti-inflammatory agents. Journal of Molecular Structure 1350:143990

doi: 10.1016/j.molstruc.2025.143990
[102]

Isa A, Banevičiūtė E, Piskin E, Cetinkaya A, Atici EB, et al. 2026. Design of an electrochemical sensor based on molecularly imprinted polymers for sensitive and selective detection of the JAK inhibitor baricitinib. Journal of Pharmaceutical and Biomedical Analysis 267:117154

doi: 10.1016/j.jpba.2025.117154
[103]

Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, et al. 2016. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. The New England Journal of Medicine 375:819−829

doi: 10.1056/NEJMoa1604958
[104]

Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L. 1998. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. The Biochemical Journal 334:297−314

doi: 10.1042/bj3340297
[105]

Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, et al. 2010. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. The New England Journal of Medicine 363:1117−1127

doi: 10.1056/NEJMoa1002028
[106]

McNally R, Eck MJ. 2014. JAK–cytokine receptor recognition, unboxed. Nature Structural & Molecular Biology 21:431−33

doi: 10.1038/nsmb.2824
[107]

Tong X, Qiao S, Dong Z, Zhao X, Du X, et al. 2024. Targeting CSF1R in myeloid-derived suppressor cells: insights into its immunomodulatory functions in colorectal cancer and therapeutic implications. Journal of Nanobiotechnology 22:409

doi: 10.1186/s12951-024-02584-4
[108]

Yu H, Pardoll D, Jove R. 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Reviews Cancer 9:798−809

doi: 10.1038/nrc2734
[109]

Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, et al. 2003. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. The Biochemical Journal 374:1−20

doi: 10.1042/bj20030407
[110]

Wang Z, Wang M, Sun Y. 2025. Vitiligo exacerbation during upadacitinib treatment for atopic dermatitis and improvement following a switch to abrocitinib: a case report. Journal of Dermatological Treatment 36:2528344

doi: 10.1080/09546634.2025.2528344
[111]

Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, et al. 2008. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. Journal of the National Cancer Institute 100:672−9

doi: 10.1093/jnci/djn123
[112]

Aggarwal BB, Shishodia S. 2006. Molecular targets of dietary agents for prevention and therapy of cancer. Biochemical Pharmacology 71:1397−1421

doi: 10.1016/j.bcp.2006.02.009
[113]

Mekheimer RA, Al-Sheikh MA, Medrasi HY, Jaragh-Alhadad L, Moustafa MS, et al. 2026. Design, synthesis, and antiproliferative activity of antipyrine linked 2-amino-quinoline-3-carbonitrile derivatives as potential dual EGFR/HER-2 inhibitors. Journal of Molecular Structure 1349:143789

doi: 10.1016/j.molstruc.2025.143789
[114]

Munir M, Forentin AM, Febrian MB, Fakih TM, Utomo RY, et al. 2025. Radiosynthesis of [131I]I-hesperidin: optimization, physicochemical profiling, and computational insights for targeted radiopharmaceuticals. Applied Radiation and Isotopes 225:111977

doi: 10.1016/j.apradiso.2025.111977
[115]

Salemi A, Zenjanab MK, Adili Aghdam MA, Sahragardan N, Esfahlan RJ. 2025. Niosome-loaded silibinin and methotrexate for synergistic breast cancer combination chemotherapy: in silico and in vitro study. Cancer Cell International 25:336

doi: 10.1186/s12935-025-03977-7
[116]

Moura SPSP, Cascante M, Rufino I, Guedes RC, Marin S, et al. 2025. Synthesis and biological evaluation of novel carnosic acid derivatives with anticancer activity. RSC Advances 15:36861−36878

doi: 10.1039/D5RA02441B
[117]

Hu H, Wang Y, Wang M, Zhang Z, Gu X, et al. 2025. Translational Research on the Oral Delivery of the Cytotoxic PROTAC Molecule via Tumor-Targeting Prodrug Strategy for Triple-Negative Breast Cancer Treatment. Journal of Medicinal Chemistry 68:20464−86

doi: 10.1021/acs.jmedchem.5c01640
[118]

Vani S, Balasubramanyam D, Karthickeyan SMK, Tirumurugan KG, Gopinathan A, et al. 2025. Genome-wide selective sweeps providing classic evidence of emotional and behavioural control in Bos indicus cattle breeds. Journal of Livestock Science 16:392−401

doi: 10.33259/jlivestsci.2025.392-401
[119]

Shang Y, Wang Q, Feng S, Du Z, Liang S, et al. 2024. Antioxidant mechanism of black garlic based on network pharmacology and molecular docking. Journal of Biobased Materials and Bioenergy 18:215−224

doi: 10.1166/jbmb.2024.2374
[120]

McCoach CE, Le AT, Gowan K, Jones K, Schubert L, et al. 2018. Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer. Clinical Cancer Research 24:3334−3347

doi: 10.1158/1078-0432.CCR-17-2452
[121]

Suehara Y, Alex D, Bowman A, Middha S, Zehir A, et al. 2019. Clinical genomic sequencing of pediatric and adult osteosarcoma reveals distinct molecular subsets with potentially targetable alterations. Clinical Cancer Research 25:6346−6356

doi: 10.1158/1078-0432.CCR-18-4032
[122]

Gorin NC. 2022. Développements thérapeutiques en hématologie au XXIe siècle. Bulletin de l'Académie Nationale de Médecine 206:952−60

doi: 10.1016/j.banm.2022.07.005
[123]

Pyne S, Pyne NJ. 2000. Sphingosine 1-phosphate signalling in mammalian cells. The Biochemical Journal 349:385−402

doi: 10.1042/bj3490385
[124]

Hunter T. 2012. Why nature chose phosphate to modify proteins. Philosophical Transactions of the Royal Society of London Series b, Biological Sciences 367:2513−2516

doi: 10.1098/rstb.2012.0013
[125]

Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. 2008. A quantitative analysis of kinase inhibitor selectivity. Nature Biotechnology 26:127−132

doi: 10.1038/nbt1358
[126]

Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, et al. 2012. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nature Medicine 18:382−384

doi: 10.1038/nm.2673
[127]

Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, et al. 2011. SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471:104−109

doi: 10.1038/nature09732
[128]

Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Mazière JC, et al. 2013. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. International Journal of Cancer 133:1732−1742

doi: 10.1002/ijc.28159
[129]

Gao S, Wang X, Zhao X, Xiao Z. 2026. Rational design of next-generation FLT3 inhibitors in acute myeloid leukemia: from laboratory to clinics. European Journal of Medicinal Chemistry 301:118214

doi: 10.1016/j.ejmech.2025.118214
[130]

Yuan Y, Wang MR, Ding Y, Lin Y, Xu TT, et al. 2025. Lenvatinib promotes hepatocellular carcinoma pyroptosis by regulating GSDME palmitoylation. Cancer Biology & Therapy 26:2532217

doi: 10.1080/15384047.2025.2532217
[131]

Guo J, Liu H, Zheng J. 2016. SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets. Nucleic Acids Research 44:D1011−D1017

doi: 10.1093/nar/gkv1108
[132]

Wang J, Wu M, Huang X, Wang L, Zhang S, et al. 2022. SynLethDB 2.0: a web-based knowledge graph database on synthetic lethality for novel anticancer drug discovery. Database 2022:baac030

doi: 10.1093/database/baac030
[133]

Ying S, Hamdy FC, Helleday T. 2012. Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1. Cancer Research 72:2814−2821

doi: 10.1158/0008-5472.c.6503301
[134]

Liu H, Zhang W, Zou B, Wang J, Deng Y, Deng L. 2020. DrugCombDB: a comprehensive database of drug combinations toward the discovery of combinatorial therapy. Nucleic Acids Research 48:D871−D881

doi: 10.1093/nar/gkz1007
[135]

Neri D, Supuran CT. 2011. Interfering with pH regulation in tumours as a therapeutic strategy. Nature Reviews Drug Discovery 10:767−777

doi: 10.1038/nrd3554
[136]

Supuran CT. 2016. Structure and function of carbonic anhydrases. The Biochemical Journal 473:2023−2032

doi: 10.1042/BCJ20160115
[137]

Pala N, Ladu F, Szlasa W, Cadoni R, Lomelino C, et al. 2025. Design, anticancer activity, and mechanistic evaluation of a novel class of selective human carbonic anhydrase IX inhibitors featuring a trifluorodihydroxypropanone pharmacophore. European Journal of Medicinal Chemistry 298:118043

doi: 10.1016/j.ejmech.2025.118043
[138]

Jung S, Strotmann R, Schultz G, Plant TD. 2002. TRPC6 is a candidate channel involved in receptor-stimulated cation currents in A7r5 smooth muscle cells. American Journal of Physiology Cell Physiology 282:C347−C359

doi: 10.1152/ajpcell.00283.2001
[139]

Soboloff J, Spassova M, Xu W, He LP, Cuesta N, Gill DL. 2005. Role of endogenous TRPC6 channels in Ca2+ signal generation in A7r5 smooth muscle cells. The Journal of Biological Chemistry 280:39786−39794

doi: 10.1074/jbc.M506064200
[140]

Kola PK, Oraegbuna CS, Lei S. 2024. Ionic mechanisms involved in arginine vasopressin-mediated excitation of auditory cortical and thalamic neurons. Molecular and Cellular Neuroscience 130:103951

doi: 10.1016/j.mcn.2024.103951
[141]

Colović MB, Krstić DZ, Lazarević-Pašti TD, Bondžić AM, Vasić VM. 2013. Acetylcholinesterase inhibitors: pharmacology and toxicology. Current Neuropharmacology 11:315−335

doi: 10.2174/1570159X11311030006
[142]

Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL. 2007. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proceedings of the National Academy of Sciences of the United States of America 104:5163−5168

doi: 10.1073/pnas.0700293104
[143]

Oğlak SC, Aşır F, Korak T, Aşır A, Yılmaz EZ, et al. 2025. Reduced M3 muscarinic acetylcholine receptor expression in gestational diabetes mellitus: implications for placental dysfunction and vascular regulation. The Journal of Maternal-Fetal & Neonatal Medicine 38:2521799

doi: 10.1080/14767058.2025.2521799
[144]

Marsh SA, Heslep N, Paronis CA, Bergman J, Negus SS, et al. 2025. Xanomeline treatment attenuates cocaine self-administration in rats and nonhuman primates. Neuropharmacology 281:110686

doi: 10.1016/j.neuropharm.2025.110686
[145]

Liu W, Putnam AL, Zhou XY, Szot GL, Lee MR, et al. 2006. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. The Journal of Experimental Medicine 203:1701−11

doi: 10.1084/jem.20060772
[146]

Bendall SC, Simonds EF, Qiu P, Amir el AD, Krutzik PO, et al. 2011. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332:687−96

doi: 10.1126/science.1198704
[147]

Chistiakov DA, Killingsworth MC, Myasoedova VA, Orekhov AN, Bobryshev YV. 2017. CD68/macrosialin: not just a histochemical marker. Laboratory Investigation 97:4−13

doi: 10.1038/labinvest.2016.116
[148]

Li S, Li J, Al Faruque H, Shami P, Knoechel B, et al. 2025. Self-assembling multi-antigen T cell hybridizers for precision immunotherapy of multiple myeloma. Advanced Healthcare Materials 14:e02156

doi: 10.1002/adhm.202502156
[149]

Furka Á. 2022. Forty years of combinatorial technology. Drug Discovery Today 27:103308

doi: 10.1016/j.drudis.2022.06.008
[150]

Hajduk PJ, Greer J. 2007. A decade of fragment-based drug design: strategic advances and lessons learned. Nature Reviews Drug Discovery 6:211−219

doi: 10.1038/nrd2220
[151]

Shi B, Zhou Y, Li X. 2022. Recent advances in DNA-encoded dynamic libraries. RSC Chemical Biology 3:407−419

doi: 10.1039/D2CB00007E
[152]

Clark MA, Acharya RA, Arico-Muendel CC, Belyanskaya SL, Benjamin DR, et al. 2009. Design, synthesis and selection of DNA-encoded small-molecule libraries. Nature Chemical Biology 5:647−54

doi: 10.1038/nchembio.211
[153]

Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, et al. 2020. Structure, function, and antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181:281−292.e6

doi: 10.1016/j.cell.2020.02.058
[154]

Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, et al. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367:1260−63

doi: 10.1126/science.abb2507
[155]

Altman JD, Moss PAH, Goulder PJR, Barouch DH, McHeyzer-Williams MG, et al. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94−96

doi: 10.1126/science.274.5284.94
[156]

Jiang B, Koo SH, Ang DSW, Ang TL, Lee HZ, et al. 2026. Development of a real-time polymerase chain reaction (RT-PCR) assay for simultaneous detection of Helicobacter pylori infection and genetic mutations associated with clarithromycin resistance: A single-center, cross-sectional study from Singapore. Diagnostic Microbiology and Infectious Disease 114:117131

doi: 10.1016/j.diagmicrobio.2025.117131
[157]

Schedin F, Geim AK, Morozov SV, Hill EW, Blake P, et al. 2007. Detection of individual gas molecules adsorbed on graphene. Nature Materials 6:652−5

doi: 10.1038/nmat1967
[158]

Josefsen LB, Boyle RW. 2012. Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics. Theranostics 2:916−66

doi: 10.7150/thno.4571
[159]

Lee KY, Mooney DJ. 2012. Alginate: properties and biomedical applications. Progress in Polymer Science 37:106−126

doi: 10.1016/j.progpolymsci.2011.06.003
[160]

Stuart MAC, Huck WTS, Genzer J, Müller M, Ober C, et al. 2010. Emerging applications of stimuli-responsive polymer materials. Nature Materials 9:101−113

doi: 10.1038/nmat2614
[161]

Cho JH, Collins JJ, Wong WW. 2018. Universal Chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173:1426−1438.e11

doi: 10.1016/j.cell.2018.03.038
[162]

Röthlisberger P, Hollenstein M. 2018. Aptamer chemistry. Advanced Drug Delivery Reviews 134:3−21

doi: 10.1016/j.addr.2018.04.007
[163]

Giraudet R, Laroche A, Chalopin B, Dubois S, Correia E, et al. 2025. Immunogenicity of single-chain antibodies: germlining of a VHH lowers T-cell activation from epitopes in FR2 and CDR regions. mAbs 17:2571406

doi: 10.1080/19420862.2025.2571406
[164]

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, et al. 2020. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. The New England Journal of Medicine 383:2603−15

doi: 10.1056/NEJMoa2034577
[165]

Millán-Martín S, Guapo F, Carillo S, Mistarz UH, Cook K, et al. 2026. Characterisation of small RNA-based therapeutics and their process impurities by fast and sensitive liquid chromatography high resolution mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 268:117097

doi: 10.1016/j.jpba.2025.117097
[166]

Cheng L, Wang T, Pi R, Zhao P, Chen J. 2025. A novel derivative of rhein overcomes temozolomide resistance in glioblastoma by regulating SOX9 through m6A methylation. Brain Research 1866:149889

doi: 10.1016/j.brainres.2025.149889
[167]

Illuminati D, Foschi R, Marchetti P, Zanirato V, Fantinati A, et al. 2025. Multi-step synthesis of chimeric nutlin-DCA compounds targeting dual pathways for treatment of cancer. Molecules 30:3908

doi: 10.3390/molecules30193908
[168]

Xie SS, Lan JS, Wang X, Wang ZM, Jiang N, et al. 2016. Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease. Bioorganic & Medicinal Chemistry 24:1528−1539

doi: 10.1016/j.bmc.2016.02.023
[169]

Zheng W, Zhao Y, Luo Q, Zhang Y, Wu K, Wang F. 2017. Multi-targeted anticancer agents. Current Topics in Medicinal Chemistry 17:3084−3098

doi: 10.2174/1568026617666170707124126
[170]

Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, et al. 2019. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resistance Updates 46:100645

doi: 10.1016/j.drup.2019.100645
[171]

Cohen L, Livney YD, Assaraf YG. 2021. Targeted nanomedicine modalities for prostate cancer treatment. Drug Resistance Updates 56:100762

doi: 10.1016/j.drup.2021.100762
[172]

Perona MTG, Waters S, Hall FS, Sora I, Lesch KP, et al. 2008. Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. Behavioural Pharmacology 19:566−574

doi: 10.1097/FBP.0b013e32830cd80f
[173]

Fathullahzadeh S, Mirzaei H, Honardoost MA, Sahebkar A, Salehi M. 2016. Circulating microRNA-192 as a diagnostic biomarker in human chronic lymphocytic leukemia. Cancer Gene Therapy 23:327−332

doi: 10.1038/cgt.2016.34
[174]

Honardoost MA, Kiani-Esfahani A, Ghaedi K, Etemadifar M, Salehi M. 2014. miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis. Gene 544:128−133

doi: 10.1016/j.gene.2014.04.069
[175]

Wang Y, Zhang S, Li F, Zhou Y, Zhang Y, et al. 2020. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Research 48:D1031−D1041

doi: 10.1093/nar/gkz981
[176]

Avillach P, Mougin F, Joubert M, Thiessard F, Pariente A, et al. 2009. A semantic approach for the homogeneous identification of events in eight patient databases: a contribution to the European eu-ADR project. Studies in Health Technology and Informatics 150:190−194

doi: 10.3233/978-1-60750-044-5-190
[177]

Avillach P, Joubert M, Thiessard F, Trifirò G, Dufour JC, et al. 2010. Design and evaluation of a semantic approach for the homogeneous identification of events in eight patient databases: a contribution to the European EU-ADR project. Studies in Health Technology and Informatics 160:1085−1089

doi: 10.3233/978-1-60750-588-4-1085
[178]

Simon J, Dos Santos M, Fielding J, Smith B. 2006. Formal ontology for natural language processing and the integration of biomedical databases. International Journal of Medical Informatics 75:224−231

doi: 10.1016/j.ijmedinf.2005.07.015
[179]

Bodenreider O. 2004. The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucleic Acids Research 32:D267−D270

doi: 10.1093/nar/gkh061
[180]

Schnell R, Bachteler T, Reiher J. 2009. Privacy-preserving record linkage using Bloom filters. BMC Medical Informatics and Decision Making 9:41

doi: 10.1186/1472-6947-9-41
[181]

Schnell R, Borgs C. Building a National Perinatal Data Base without the Use of Unique Personal Identifiers. 2015 IEEE International Conference on Data Mining Workshop (ICDMW), 2015, Atlantic City, NJ, USA. USA: IEEE. pp. 232−239 doi: 10.1109/ICDMW.2015.19
[182]

Brown EG. 2003. Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA). Drug Safety 26:145−158

doi: 10.2165/00002018-200326030-00002
[183]

Djennaoui M, Ficheur G, Beuscart R, Chazard E. 2015. Improvement of the quality of medical databases: data-mining-based prediction of diagnostic codes from previous patient codes. Studies in Health Technology and Informatics 210:419−423

doi: 10.3233/978-1-61499-512-8-419
[184]

Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, et al. 2015. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. Journal of the American Medical Informatics Association 22:553−64

doi: 10.1093/jamia/ocu023
[185]

Stadler CB, Lindvall M, Lundström C, Bodén A, Lindman K, et al. 2021. Proactive construction of an annotated imaging database for artificial intelligence training. Journal of Digital Imaging 34:105−115

doi: 10.1007/s10278-020-00384-4